Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-090925
Filing Date
2024-08-05
Accepted
2024-08-05 17:01:29
Documents
55
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tern-20240630.htm   iXBRL 10-Q 1646815
2 EX-10.1 tern-ex10_1.htm EX-10.1 64444
3 EX-31.1 tern-ex31_1.htm EX-31.1 16202
4 EX-31.2 tern-ex31_2.htm EX-31.2 16199
5 EX-32.1 tern-ex32_1.htm EX-32.1 8899
6 EX-32.2 tern-ex32_2.htm EX-32.2 8899
  Complete submission text file 0000950170-24-090925.txt   7946510

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tern-20240630.xsd EX-101.SCH 1293994
57 EXTRACTED XBRL INSTANCE DOCUMENT tern-20240630_htm.xml XML 1446865
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39926 | Film No.: 241175824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)